On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to bed. AbbVie's Allergan has agreed to pay New York state $200 million by the middle of next year to resolve claims that it helped fuel a statewide opioid epidemic, New York Attorney General Letitia James said in a release Wednesday. More than $150 million of the settlement will go toward opioid treatment and abatement in communities hard hit by the crisis, James added.